Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.

Phase 3

Vertex Pharmaceuticals Incorporated

Cystic Fibrosis Foundation
Cystic Fibrosis Foundation Therapeutics

Ivacaftor